Originations: In the first quarter of 2025, Runway Growth funded three investments in existing portfolio companies. These include: Completion of a new $55 million investment to existing portfolio company, Route 92 Medical funding $35 million at close, which refinanced Route 92’s existing senior term loan; Completion of a $13 million follow-on investment to existing portfolio company, Elevate Services; and Completion of a new $2.7 million investment to existing portfolio company, Marley Spoon SE. “In the first quarter of 2025, Runway Growth originated high quality financing solutions to several of our existing portfolio companies within the resilient sectors of technology, healthcare and consumer services,” said David Spreng, Founder and CEO of Runway Growth. “As we navigate the current market environment, we are focused on underwriting discipline in our continued effort to preserve credit quality. With the close of the acquisition of Runway Growth’s investment adviser by affiliates of BC Partners Advisors L.P. in the first quarter of 2025, we are leveraging our shared expertise and resources to act thoughtfully on attractive opportunities that we believe will drive growth and deliver value for our shareholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RWAY:
- Runway Growth Finance price target lowered to $11 from $13 at UBS
- Runway Growth Finance price target raised to $12 from $11.50 at Compass Point
- Runway Growth Finance upgraded to Buy from Neutral at Lucid Capital
- Runway Growth Finance Q4 2024 Earnings Call Insights
- Runway Growth Finance extends credit facility, expands size of board